Profound Medical Corp.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.33 | — | — |
| 2026-05-07 | -0.25 | -0.19 | +25.20% |
| 2026-03-05 | -0.27 | -0.27 | +1.22% |
| 2025-11-13 | -0.38 | -0.26 | +30.85% |
| 2025-08-14 | -0.40 | -0.52 | -30.82% |
| 2025-05-08 | -0.28 | -0.36 | -27.43% |
| 2025-03-06 | -0.32 | -0.20 | +37.98% |
| 2024-11-07 | -0.30 | -0.38 | -25.62% |
| 2024-08-08 | -0.28 | -0.28 | +1.75% |
| 2024-05-09 | -0.31 | -0.26 | +15.22% |
| 2024-03-07 | -0.32 | -0.42 | -32.43% |
| 2023-11-02 | -0.32 | -0.26 | +19.75% |
| 2023-08-09 | -0.34 | -0.35 | -1.74% |
| 2023-05-10 | -0.34 | -0.32 | +6.57% |
| 2023-03-07 | -0.37 | -0.34 | +9.22% |
| 2022-11-03 | -0.38 | -0.24 | +36.60% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| PROF | -0.73% | -8.96% | -13.47% | +24.04% |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | -3.70% | -4.13% | -10.03% | +11.42% |